Osi Pharmaceuticals, Inc.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
8
Ending by 2030
Feb 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 15, 2027The maintenance fee for Macrocyclic kinase inhibitors (US 9,133,224) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 1 fee due Jun 5, 2027The maintenance fee for Pulse dosing regimen and methods of treatment (US 11,833,149) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
- 1 fee due Sep 10, 2027The maintenance fee for Pulse dosing regimen and methods of treatment (US 10,583,142) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.
Recent changes
- 4 terms have ended since Aug 23, 2026
- Nov 15 US 8,796,455 Fused bicyclic mTOR inhibitors · term ended
- Nov 15 US 8,314,111 Fused bicyclic motor inhibitors · term ended
- Nov 15 US 7,943,767 Fused bicyclic mTOR inhibitors · term ended
- Nov 15 US 7,923,555 Fused bicyclic mTor inhibitors · term ended
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,951,405 | Combined treatment with cisplatin and an epidermal growth factor receptor kinase inhibitor In force · USPTO record | In force | USPTO record | |
| US 7,651,687 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors In force · USPTO record | In force | USPTO record | |
| US 8,114,846 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors In force · USPTO record | In force | USPTO record | |
| US 8,586,546 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors In force · USPTO record | In force | USPTO record | |
| US 7,700,594 | Fused bicyclic mTOR inhibitors In force · USPTO record | In force | USPTO record | |
| US 7,939,272 | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors In force · USPTO record | In force | USPTO record | |
| US 8,575,164 | Combination cancer therapy In force · USPTO record | In force | USPTO record | |
| US 8,481,733 | Substituted imidazopyr- and imidazotri-azines In force · USPTO record | In force | USPTO record | |
| US 8,445,510 | Fused bicyclic kinase inhibitors In force · USPTO record | In force | USPTO record | |
| US 8,399,433 | Amino pyrimidine anticancer compounds In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 14: 2 patents in force now held by others · 157 lapsed for an unpaid fee · 76 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 abandoned · 27 no status recorded